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Abstract
Dimethylarsinic acid (DMA(V)) is a rat bladder carcinogen and the major urinary metabolite of
administered inorganic arsenic in most mammals. This study examined the disposition of pentavalent
and trivalent dimethylated arsenic in mice after acute oral administration. Adult female mice were
administered [14C]-DMA(V) (0.6 or 60 mg As/kg) and sacrificed serially over 24 h. Tissues and
excreta were collected for analysis of radioactivity. Other mice were administered unlabeled DMA
(V) (0.6 or 60 mg As/kg) or dimethylarsinous acid (DMA(III)) (0.6 mg As/kg) and sacrificed at 2 or
24 h. Tissues (2 h) and urine (24 h) were collected and analyzed for arsenicals. Absorption,
distribution and excretion of [14C]-DMA(V) were rapid, as radioactivity was detected in tissues and
urine at 0.25 h. For low dose DMA(V) mice, there was a greater fractional absorption of DMA(V)
and significantly greater tissue concentrations of radioactivity at several time points. Radioactivity
distributed greatest to the liver (1–2% of dose) and declined to less than 0.05% in all tissues examined
at 24 h. Urinary excretion of radioactivity was significantly greater in the 0.6 mg As/kg DMA(V)
group. Conversely, fecal excretion of radioactivity was significantly greater in the high dose group.
Urinary metabolites of DMA(V) included DMA(III), trimethylarsine oxide (TMAO),
dimethylthioarsinic acid and trimethylarsine sulfide. Urinary metabolites of DMA(III) included
TMAO, dimethylthioarsinic acid and trimethylarsine sulfide. DMA(V) was also excreted by DMA
(III)-treated mice, showing its sensitivity to oxidation. TMAO was detected in tissues of the high
dose DMA(V) group. The low acute toxicity of DMA (V) in the mouse appears to be due in part to
its minimal retention and rapid elimination.
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Introduction
Arsenic is of concern to public health organizations because of its many different forms, its
prevalence in the environment and exposure to it may result in adverse health outcomes.
Exposure to the organic arsenical dimethylarsinic acid (DMA (V)) occurs from external and
internal sources. Regarding external exposure, DMA(V) is found naturally in surface waters
at levels ranging from 0.04 to 1 ppb (Braman and Foreback, 1973) and is used as a non-selective
herbicide and a cotton desiccant (US EPA, 1975). Concerning internal exposure, DMA (V) is
a major metabolite of inorganic arsenic (iAs) (Vahter, 1994) of most mammals as well as a
metabolite of arsenosugars found in edible seaweed (Wei et al., 2003).
DMA(V) is readily absorbed by laboratory animals after oral administration (Buchet et al.,
1981; Marafante et al., 1987; Stevens et al., 1977; Vahter et al., 1984; Yamauchi and
Yamamura, 1984). The rat and mouse absorb from 65% to 85% of an oral dose of DMA(V)
(Marafante et al., 1987; Stevens et al., 1977; Vahter et al., 1984), while the hamster absorbs
less (ca. 50%) (Yamauchi and Yamamura, 1984). Humans also absorb DMA(V) following oral
administration to volunteers (Buchet et al., 1981; Marafante et al., 1987) or occupational
exposure (Tarrant and Allard, 1972; Wagner and Weswig, 1974). Absorbed DMA(V) is
excreted rapidly in urine by most mammals (Hughes and Kenyon, 1998; Marafante et al.,
1987; Vahter et al., 1984). However, the rat is unique, as it avidly retains DMA(V) (Stevens
et al., 1977; Vahter et al., 1984), resulting in an unusually long whole-body half life of this
arsenical. DMA(V) is reduced in vivo to dimethylarsinous acid (DMA(III)), which the rat red
blood cell effectively takes up (Shiobara et al., 2001). DMA(III) binds specifically to
cysteine-13-alpha of rat hemoglobin, more strongly than other arsenic compounds (Lu et al.,
2004, 2007).
In vivo laboratory studies conducted 15–20 years ago report that DMA(V) is excreted in urine
primarily unchanged after oral and parenteral administration (Marafante et al., 1987; Vahter
et al., 1984; Yamauchi and Yamamura, 1984). It was observed that 4–15% of the dose of DMA
(V) administered orally was excreted as a trimethylarsenic compound in urine of the hamster
(Marafante et al., 1987; Yamauchi and Yamamura, 1984), mouse (Marafante et al., 1987), rat
(Chen et al., 1996; Yoshida et al., 1997, 1998) and man (Marafante et al., 1987). This compound
has been identified as trimethylarsine oxide (TMAO) (Marafante et al., 1987; Yoshida et al.,
1997). Current studies with improved analytical techniques have detected DMA(III) and
dimethylthioarsenicals in tissues and urine of animals exposed to DMA(V) (Cohen et al.,
2002; Lu et al., 2003; Suzuki et al., 2004a; Yoshida et al., 2003). There are reports that DMA
(V) is demethylated in vivo to monomethylarsonic acid (MMA(V)) and inorganic arsenic (iAs),
products which were detected in the urine of DMA(V)-treated rats (Chen et al., 1996; Yamauchi
and Yamamura, 1984; Yoshida et al., 1997). However, demethylated products of administered
DMA (V) have not been reported by other investigators using rats, mice, hamsters or human
volunteers (Buchet et al., 1981; Hughes et al., 2000; Marafante et al., 1987; Stevens et al.,
1977; Vahter et al., 1984).
The acute toxic effects of DMA(V) are minimal (Kenyon and Hughes, 2001); the oral LD50
of DMA(V) ranges from 644 to 1800 mg/kg in the rat and mouse (Gaines and Linder, 1986;
Kaise et al., 1989). The acute in vivo effects of DMA(III) are not known, but it is more highly
cytotoxic than DMA(V) (Cohen et al., 2002; Dopp et al., 2004; Styblo et al., 2000). In contrast
to its relatively low acute toxic potency, DMA(V) is a multiorgan tumor promoter in mice
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(Yamanaka et al., 1996, 2000) and rats (Li et al., 1998; Wanibuchi et al., 1996; Yamamoto et
al., 1995) and a complete carcinogen for rat urinary bladder following chronic exposure in
drinking water (50–200 ppm) (Wei et al., 1999, 2002) or the diet (100 ppm) (Arnold et al.,
2006). Knowledge of the metabolic fate of arsenic derived from orally administered DMA(V)
will facilitate evaluation of the role of DMA(V) and its metabolites in arsenic-induced toxicity.
The objective of the present study was to examine the dosage dependency on the tissue
dosimetry, metabolism and excretion of arsenicals following the oral administration of DMA
(V) or DMA(III) in the mouse.
Methods
Chemicals
[14C]-Dimethylarsinic acid (specific activity, 10 mCi/mmol) was purchased from ICN
Radiochemicals (Irvine, CA, USA). The radiochemical purity of the compound was greater
than 98% (Hughes and Thompson, 1996). Unlabeled DMA(V) (90% purity, 9% MMA(V), 1%
iAs) was from Ansul (Weslaco, TX, USA). Dimethylarsine iodide (purity, 98%) and TMAO
(purity > 98%) were synthesized by Dr. William Cullen (University of British Columbia,
Vancouver, British Columbia, Canada). Carbosorb E, Permafluor E and Ultima Gold were
obtained from Perkin Elmer (Meriden, CT, USA). Sodium borohydride, sodium hydroxide and
ACS certified hydrochloric acid were purchased from EM Science (Gibbstown, NJ, USA).
Antifoam B silicone emulsion and phosphoric acid (Ultrex grade) were obtained from
Mallinckrodt Baker, Inc. (Phillipsburg, NJ, USA). All other chemicals used were of the highest
grade commercially available.
Animals
Female B6C3F1 mice were obtained from Charles River Laboratories (Raleigh, NC, USA).
The mice were housed in a facility approved by the American Association for Accreditation
of Laboratory Animal Care and maintained according to the guidelines in the National Institutes
of Health Guide on the Care and Use of Laboratory Animals. The animals were initially group
housed in polycarbonate cages with bedding of heat-treated pine shavings. The mice were
provided Prolab RMH300 (Purina, St. Louis, MO, USA) (containing <1 ppm As) and tap water
ad libitum throughout the experiment. The animal room was on a 12/12-h light/dark cycle and
the temperature and humidity were 22±1 °C and 50±10%, respectively. The mice were moved
to metabolism cages (Nalge Co., Rochester, NY, USA) 3 days before the experiment began.
On the day of dosing, the average weight of the animals was 25 g and they ranged in age from
90 to 120 days.
Experimental
In the dosimetry study, mice were administered [14C]-DMA (V) (2 μCi) at dosage levels of
0.6 and 60 mg As/kg body weight. These dosages correspond to 1.11 and 111 mg/kg of DMA
(V), respectively. The dosing solutions were prepared in HPLC-grade water (Burdick and
Jackson, Muskegon, MI) and administered orally (10 ml/kg). The mice were housed in
individual metabolism cages after dosing. At selected time points (0.25, 0.5, 1, 2, 4, 8, 12 or
24 h), four mice at each dosage level of DMA(V) were sacrificed by cardiac puncture under
CO2-induced anesthesia. Kidney, liver, lung and urinary bladder were removed from the mice.
The blood and organs were weighed, frozen in liquid nitrogen and stored at −70 °C until
processed for radioassay by combustion in a Perkin Elmer model D307 oxidizer. Urine and
feces were collected from each metabolism cage at the time of sacrifice. Each metabolism cage
was washed with approximately 75 ml of 10% (v/v) Count-Off (Perkin Elmer). This wash was
mixed with the urine and brought to a total volume of 100 ml. Aliquots of the combined urine
and cage wash were mixed with scintillant and radioassayed in a Perkin Elmer model 2560
liquid scintillation counter. The feces were weighed and combusted before radioassay.
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In the metabolism study, mice were administered unlabeled DMA(V) (0.6 or 60 mg As/kg) or
DMA(III) (0.6 mg As/kg) by oral gavage (10 ml/kg). Three mice for each dosage group were
housed individually in metabolism cages and urine was collected cold for 24 h. Three control
mice were administered water. Urine samples were analyzed for speciated arsenic on the day
of collection by hydride generation-atomic absorption spectroscopy (HG-AAS) as described
below. Other 24-h urine samples were frozen at −70 °C until analyzed by mass spectrometry
for methylated thioarsenic compounds as described below. Another group of mice (N=3/group)
were similarly treated but sacrificed 2 h post-administration of DMA(V), DMA(III) or water.
Blood, kidney, liver, lung and urinary bladder were removed from these mice, weighed, frozen
in liquid nitrogen and stored at −70 °C. At a later time, these tissues were digested in ultra pure
phosphoric acid and analyzed by HG-AAS as described below.
Atomic absorption spectrometry of arsenicals
Urine and acid digested tissues of mice treated with DMA(V), DMA(III) or water were
analyzed by HG-AAS as described by Devesa et al. (2004) with some modifications based on
Hernandez-Zavala et al. (in press). Briefly, arsines are generated from arsenicals within the
samples using sodium borohydride. The arsines are flushed into a U-tube, which is packed with
15% OV-3 (coated C-18) (Supelco, Inc., Bellefonte, PA, USA). Arsines are cryotrapped onto
the chromatography packing by immersing the U-tube in liquid nitrogen. After 3 min, the liquid
nitrogen is removed and the U-tube is heated, thereby separating the arsines on their boiling
point. The volatilized arsines are then flushed into a heated multiatomizer and detected with
an electrodeless discharge lamp at a wavelength of 197.3 nm.
Aliquots of urine were analyzed without acid digestion. Kidney, liver and lung homogenates
were prepared in deionized water at a ratio of 1 g tissue to 5 ml water. Because of their small
size, the urinary bladders were digested in phosphoric acid without homogenization. Three
milliliters of 2 M phosphoric acid was mixed with no more than 0.025 g of tissue (0.125 ml of
homogenate) or 0.01 ml of blood. This mixture was heated at 90 °C in a water bath overnight
to digest the sample.
For quantitation of DMA(III) and TMAO in urine, arsines were generated after injection of a
urine sample into a flow of deionized water, which was then mixed with 0.75 M Tris–HCL
buffer (pH 6) and 1% (w/v) NaBH4 in 0.1% (w/v) NaOH. For quantitation of TMAO in acid-
digested tissues, sodium hydroxide (10.9 M, 0.2 ml/ml digest) was first added to cooled tissue
digests, to adjust the pH to 6, before trimethylarsine was generated as described above. For
quantitation of total DMA (DMA(V)+DMA(III) species), sodium hydroxide (10.9 M, 0.2 ml/
ml sample) was added to urine and cooled tissue digests to adjust the pH to 6, followed by pre-
treatment with 2% L-cysteine for 70 min to reduce all arsenicals to trivalent forms before
dimethylarsine was generated as described above.
Mass spectrometric determination of thioarsenicals
Urine samples were analyzed for dimethylthioarsinic acid (DMTA) and trimethylarsine sulfide
(TMAS) using reverse phase chromatography inductively coupled plasma mass spectrometry
(HPLC-ICP-MS). An Agilent 1100 HPLC system (Palo Alto, CA, USA) was used for all
chromatography. A Phenomenex (Torrance, CA, USA) Intersil 5 μ ODS-2 (C-18) column with
a flow rate of 0.5 ml/min and an injection volume of 100 μl was used. The mobile phase was
2.5 mM tetramethylammonium hydroxide (Alfa, Danvers, MD, USA), 1.1 mM disodium
malonate (Sigma) in 5% (wt/wt) methanol (Optima, Fisher Scientific, Pittsburgh, PA, USA),
adjusted to pH 6.1 with acetic acid (TraceMetal grade, Fisher Scientific). Urine samples were
diluted 10- to 1000-fold for detection with mobile phase in acid-rinsed autosampler vials
(Target DP, National Scientific Co., Duluth, GA, USA).
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An Agilent 7500a inductively coupled mass spectrometer (ICP-MS) was used for detection
(m/z=75) and quantitation of the methylated thioarsensicals. Quantitation of DMTA and TMAS
was based on comparison of integrated peak areas from 100 μl sample injections with those of
known standards. Three separate standard solutions were used because long-term stabilities
(i.e., weeks) of standard mixtures containing DMTA and TMAS have not been verified in a
laboratory environment. One standard contained DMA(V), MMA(V) (98% purity, Chem
Service, West Chester, PA, USA) and arsenate (Spex Certiprep, Metuchen, NJ, USA). The
other two standards contained DMTA or TMAS prepared by bubbling H2S (generated by
reacting FeS and HCl) through a solution containing DMA(V) or TMAO in 18 Ω distilled
deionized water (Fricke et al., 2005). The structures of the prepared DMTA and TMAS were
determined by reverse phase HPLC-electrospray ionization-mass spectrometry as described
by Adair et al. (2007). Identification of the thioarsenicals in mouse urine was by co-
chromatography with these known standards of DMTA and TMAS. All standards were
prepared on the basis of arsenic content and are analytically traceable to SRM 1640 (trace
elements in natural water, NIST, Gaithersburg, MD, USA). Samples were analyzed by
standardizing (using the three standard solutions) and verifying standardization after every six
samples and at the end of a sample set.
Data analysis
Data are presented as mean±SD throughout the text. Data were analyzed statistically by SAS
System for Windows Version 8.2 (SAS Institute, Cary, NC, USA). Urinary, fecal and tissue
data were analyzed by PROC GLM with classifications of dose and time. Significant dose
effects were further tested at each time point using Fisher's significant difference test. Effects
were considered significant at P< 0.05. PK Solutions Version 2.06 (Summit Research Services,
Montrose, CO, USA) was used to estimate area under the curve (AUC) for the arsenic tissue
concentration–time profiles. The systemic bioavailability (F) for each dose of administered
DMA(V) was estimated by the equation F=(Xpo/Xiv), where X represents the 24-h amount of
DMA(V)-derived radioactivity excreted in urine after po or iv administration. Data from the
iv administration study were from Hughes and Kenyon (1998). Clearance (CL) of DMA(V)-
derived radioactivity from blood was estimated by the equation CL=(dose*F)/AUCblood.
Results
DMA(V)-derived radioactivity was detected in urine and all tissues examined by 15 min post-
administration, indicating that the processes of absorption, distribution and elimination of this
compound occur rapidly in the mouse. The distribution of DMA (V)-derived radioactivity,
based on % dose, was widespread throughout the tissues, but the levels were low (Fig. 1). Peak
levels of radioactivity were detected 1–2 h post-administration and were highest in liver (high
dose—1.27%; low dose—1.81%), followed by kidney, lung and urinary bladder. Significant
differences with respect to dose were detected within 2 h post-administration in the distribution
of radioactivity to kidney, liver and lung (Fig. 1). In these cases, there was a significantly greater
% of the dose detected in the tissues of the low dose group than in tissues of the high dose
group. At 24 h, less than 0.05% of the dose remained in the tissues examined, suggesting that
this compound is not retained by the mouse.
Tissue concentrations of DMA(V)-derived radioactivity, based on % dose/g, peaked 1–2 h
after administration in all tissues at both dosage levels, except for the urinary bladder at the
high dosage level (Fig. 2). In the latter case, the peak concentration was at 4 h. The peak
concentrations of DMA(V)-derived radioactivity in the kidney, liver, lung and urinary bladder
were greater than those in the blood, indicating that the compound had distributed from the
blood into these organs. Peak concentrations of radioactivity were greatest in lung and kidney
(high dose—2.5% dose/g; low dose—2.2 and 2% dose/g, respectively), followed by liver,
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urinary bladder and blood for both dosages of DMA(V). Significant dose effects on the relative
concentration of DMA-derived radioactivity were detected in lung, blood, liver and kidney at
several time points (Fig. 2). These differences occurred within 4 h post-exposure and in all
cases, the relative concentration of DMA(V)-derived radioactivity in tissues of the low dose
group was significantly greater than in tissues of the high dose group.
Tissue concentration–time profiles of DMA(V)-derived radioactivity (Fig. 3), based on ng As/
g, appeared parallel for both dosages of DMA(V). The arsenic concentration (ng As/g) in each
tissue of the high dose group was consistently greater than that in the low dose group. However,
the ratios of high to low dose AUC were less than 100, suggesting that there were dose-
dependent effects in the disposition of DMA(V) (Table 1). For both dosage levels, the lung
was the tissue with the highest AUC. At the low dose, lung was followed by urinary bladder,
kidney, liver and blood. At the high dose, lung was followed by kidney, urinary bladder, liver
and blood. The elimination half-life of DMA-derived radioactivity was similar at both dosages
of DMA(V) for blood, lung and kidney and ranged from 5 to 8 h (Table 1). The elimination
half-life in the urinary bladder had a similar value at the low dose as the latter organs but
increased to about 16 h at the high dose. Of all tissues examined, the elimination half-life was
longest in the liver: 14 h at the low dose and 38 h at the high dose of DMA(V).
The systemic bioavailability of DMA(V)-derived radioactivity was estimated as 0.88 and 0.48
for the 0.6 and 60 mg As/kg dose, respectively. The clearance of DMA(V)-derived radioactivity
from blood was estimated as 33 and 21 g/h for the 0.6 and 60 mg As/kg dose, respectively.
The 24-h cumulative urinary elimination of DMA(V)-derived radioactivity was 65% and 37%
of the administered dose for the low and high dose groups, respectively (Fig. 4). The percentage
of the dose excreted in urine by the low dose group was significantly greater than that excreted
by the high dose group at 8, 12 and 24 h.
The 24-h cumulative fecal excretion of DMA(V)-derived radioactivity was 49% and 71% of
the administered dose for the 0.6 and 60 mg As/kg dose groups, respectively (Fig. 4). In contrast
to the urinary excretion data, the high dose group excreted a significantly greater percentage
of the dose in feces than the low dose group at 8, 12 and 24 h.
Low levels of DMA(V), DMA(III) and TMAO were detected by HG-AAS in the urine of
control animals (Table 2). Following administration of DMA(V) or DMA(III) to the mice,
DMA(V), DMA(III) and TMAO concentrations in urine increased. An exception to this
response was seen in the DMA(V) low dose group, in which excretion of DMA(III) remained
at control levels. For DMA(V) at the 0.6 mg As/kg dose, similar concentrations of DMA(V)
and TMAO were found in urine. At the higher dose of DMA(V), levels of parent compound
and of the two metabolites exceeded those found in the low dose group. MMA(V) was also
detected in this group and is most likely from that in the dosing solution. In the DMA(III)-
treated group, TMAO was the predominant urinary metabolite and similar levels of DMA(III)
and DMA(V) were found. The presence of DMA(V) in the urine of the DMA(III)-treated group
shows that oxidation of DMA(III) occurred spontaneously in vivo, as a component of
metabolism or in voided urine.
The methylated thioarsenicals, DMTA and TMAS, were excreted in urine of control and DMA
(V) and DMA(III)-treated mice (Table 3). In DMA(III)- and DMA(V)-exposed mice,
concentrations of DMTA and TMAS in urine were 6- to 50-fold greater than those found in
control urine. Urinary concentrations of DMTA and TMAS were similar in DMA(V)- and
DMA(III)-treated mice, suggesting that the dosage level or oxidation state of arsenic did not
affect the excretion of DMTA or TMAS.
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DMA was the predominant arsenical in tissues of mice 2 h after oral administration of DMA
(V) or DMA(III) (Table 4). Because tissues were solubilized in phosphoric acid as a prelude
to HG-AAS analysis, the oxidation state of arsenic present in various arsenicals in tissues
cannot be determined. Therefore, the values for iAs and mono- and dimethylated arsenic are
reported as total speciated arsenic (iAs(III+V), MMA(III+V) and DMA(III+V)). TMAO was
detected consistently in kidney for both doses of DMA(V) and in liver, lung and urinary bladder
of the high dose group. TMAO was detected in the liver and lung of one sample from the DMA
(III)-treated group and low dose DMA(V) group in the liver. At 2 h, the lung was the organ
with the highest concentration of arsenic and the predominant species was DMA. The MMA
that was detected is most likely from that within the original DMA(V) dosing solution, which
contained approximately 9% MMA(V).
Discussion
The absorption, distribution and excretion of DMA(V) by mice were rapid after oral
administration. DMA(V)-derived radioactivity was detected in urine and all tissues by 15 min
post-treatment. A similar pattern of rapid absorption, distribution and excretion of radioactivity
was observed in mice of the same strain and sex after oral treatment with [14C]-MMA(V)
(Hughes et al., 2005), a metabolic precursor of DMA(V).
The oral absorption of DMA(V) appears to be dose dependent in mice with reduced fractional
absorption at the higher dosage. This also occurs in mice with orally administered MMA(V)
(Hughes et al., 2005). In the present study, with increased administered dose of DMA(V), the
systemic bioavailability decreased, the ratio of the tissue AUCs based on dose were less than
100-fold and there was increased fecal excretion and decreased urinary excretion of DMA(V)-
derived radioactivity. Also, at the times where there were significant dose-related differences
in tissue concentration of radioactivity, the concentrations in the low dosage group exceeded
those of the high dosage group.
Excretion of orally administered DMA(V) occurs rapidly in the mouse. In the present study,
approximately 75% of either dose of DMA(V) was excreted in urine and feces within 8 h of
treatment. With MMA(V), 80% of an oral dose (0.4 or 40 mg As/kg) was excreted in urine and
feces within 8 h (Hughes et al., 2005). Our DMA(V) data are also consistent with other
published results in mice, which reported that 95% of an oral dose of DMA (V) (0.4 or 40 mg
As/kg) was excreted in urine and feces by 24–48 h (Marafante et al., 1987; Vahter et al.,
1984). However, a major difference was the greater percentage of urinary TMAO that was
detected in the present study (18–49%) than reported by Marafante et al. (1987) (5%). This
difference may be due to strain and sex of the mouse model used and analytical sensitivity
between methods used by Marafante et al. (1987) and those used in the present study. Humans
also absorb and excrete DMA(V) rapidly. In volunteers, approximately 57–65% of an oral dose
of DMA(V) (~7 to 100 μg As/kg) was excreted in urine within 24 h (Buchet et al., 1981;
Marafante et al., 1987).
The current study found that there was a dose-dependent decrease in the percentage of DMA
(V) excreted in urine and a concomitant dose-dependent increase in the percentage of DMA
(V) excreted in feces. This pattern is consistent with findings in MMA(V)-treated mice (Hughes
et al., 2005). In rats, biliary excretion of DMA(V) or MMA(V) is less than 1% of the dose after
intravenous administration (Cui et al., 2004; Gregus et al., 2000; Suzuki et al., 2004a). Similar
data on the biliary excretion of DMA(V) and its metabolites in the mouse are lacking. Fecal
excretion of DMA(V) administered intravenously to mice at the same dosages as in the present
study is less than 5% of the dose (Hughes and Kenyon, 1998), suggesting that biliary excretion
of administered DMA(V) is limited in this species. Urinary excretion of DMA(V) administered
intravenously to mice is not affected by dose (Hughes and Kenyon, 1998). The latter
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observations and present data suggest that the radioactivity detected in feces of mice treated
orally with [14C]-DMA(V) is likely unabsorbed parent compound and also suggests that
gastrointestinal absorption of DMA(V) was dose dependent.
Accumulation of DMA in lungs of DMA(V)-treated mice suggests a particular affinity of this
organ for dimethylated arsenicals. For both doses of DMA(V), the lung had the highest peak
concentration of DMA(V)-derived radioactivity and the highest AUC among the tissues. In
addition, the lung had the highest concentration of total DMA among all HG-AAS analyzed
tissues from DMA(V)- and DMA(III)-treated mice. The accumulation of DMA in lung also
occurs in mice after intravenous administration of this compound (Hughes et al., 2000; Vahter
et al., 1984). Following acute oral exposure, DMA(V)-derived radioactivity in the lung
disappeared quickly from this tissue, with a terminal half-life of 6 h. However, the short
residence of DMA in the lung is sufficient to produce an adverse effect. An acute oral dose of
DMA(V) (1.5 g/kg, sodium salt) induces oxidative damage in mouse lung by 6 h post-
administration (Yamanaka et al., 1991). Also, DMA(V) in drinking water (400 ppm) promotes
lung tumor development in the A/J mouse strain (which is spontaneously susceptible to
pulmonary tumors) (Hayashi et al., 1998) and the ddY mouse strain pre-treated with 4-
nitroquinoline 1-oxide (Yamanaka et al., 1996).
Rats fed a diet containing 100 ppm of DMA(V) develop urothelial cell carcinomas after a 2-
year exposure (Arnold et al., 2006). In contrast, mice fed up to 500 ppm DMA(V) in the diet
do not develop treatment-related tumors at any site (Arnold et al., 2006). DMA(III), a reduced
metabolite of DMA(V), has been postulated to be the toxic moiety that elicits the carcinogenic
effect in DMA(V)-exposed rats (reviewed in Cohen et al., 2006). Cohen et al. (2002) reported
that the LC50 of DMA(III) in rat and human urothelial cell lines to be less than 1 μM; the
LC50 for either DMA(V) or TMAO in these cell lines was in the millimolar range. Similarly,
in Urotsa cells, a human SV-40 transformed urothelial cell line, the LC50 for DMA(III)-
glutathione complex was 14 μM and DMA(V) was inactive at the concentrations tested (Styblo
et al., 2000). Thus, dimethylated arsenic in the trivalent oxidation state is highly cytotoxic,
exceeding both DMA(V) and TMAO in potency. In the present study, the concentration of
DMA(III) in urine of the high dose DMA(V)-treated mice was approximately 90 μM. This far
exceeded the concentration of DMA(III) (1.4 μM) found in urine of rats fed a diet of 100 ppm
of DMA(V) for 24 h (Lu et al., 2003). The lower concentration of DMA(III) in urine of DMA
(V)-treated rats might reflect oxidation of trivalent arsenic occurring during sample collection,
shipment and processing. It may also be based on administered dose because the rats exposed
to 100 ppm DMA(V) received approximately 5.4 mg As/kg (assuming 80 g rat and 10 g food
consumed/day/100 g body weight), whereas the mice in the present study received
approximately a 10-fold greater dose. Data in the literature to allow a direct comparison
between levels of metabolites in mouse and rat urine after exposure to DMA(V) are somewhat
sparse, particularly in regard to the more unstable or difficult to detect metabolites. Such a
comparison would be of interest because of the differences in responsiveness between rat and
mouse urothelium observed during lifetime exposure to DMA (V) in the diet (Arnold et al.,
2006). In addition, the proposed mode of action for DMA(V)-induced bladder cancer in rats
is cytotoxicity and regenerative proliferation which requires prolonged and relatively
continuous exposure to the putative toxic agent. Thus, any such comparison to be meaningful
needs to be made in animals whose urinary metabolite excretion has reached steady state levels,
which would take place in a few days in the mouse but would require weeks in the rat. Data
currently available allow one to propose but not ascribe with certainty causation of the lesions
in rat urothelium to DMA(III) or one of the other recently identified methylated thioarsenic
metabolites.
The concentration of urinary TMAO was 32 μM and 740 μM in the low and high dose groups
of DMA(V), respectively. These data show that the mouse is quite capable of reducing and
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methylating DMA(V) to TMAO. However, a fair percentage of the excreted arsenic was in the
form of parent DMA(V) (> 50%). Adair et al. (2007) have reported that rats exposed to 100
ppm of DMA(V) in drinking water for 14 days excrete a TMAO concentration of 1200 μM.
This value is consistent with that reported for rats treated with an acute oral dose of 50 mg/kg
DMA (V) (Yoshida et al., 1997). The urinary concentration of TMAO excreted at 8 h by the
acutely treated rats was 2000 μM. The high concentration of TMAO in mouse and rat urine
after DMA(V) treatment is consistent with the formation of relatively high concentrations of
DMA(III) (90 μM in the high dose DMA(V) group) as an obligate intermediate in the pathway
for oxidative methylation of DMA(V) (reviewed in Thomas et al., 2007).
The metabolism of DMA(V) appears to be affected by administered dose. At the low dose of
DMA(V) (0.6 mg As/kg), approximately 50% of the excreted arsenic was TMAO. With a 100-
fold increase in administered dose, 20% of the urinary excreted arsenic was in the form of
metabolites (DMA(III) and TMAO). This would suggest that the potential uptake of DMA (V)
by arsenic metabolizing cells was saturated, or that the reduction and methylation of this
arsenical in these cells was similarly affected. Marafante et al. (1987) reported that in mice 80–
85% of an acute oral dose of DMA(V) (40 mg As/kg) was eliminated as unmetabolized DMA
(V). Some of this excreted dimethylated arsenic may have been DMA(III), as the analytical
techniques to speciate trivalent and pentavalent DMA were not developed at the time this paper
was published. The important observation is that the percentage of methylated DMA(V)
decreases as DMA(V) dose increases.
The detection of unknown arsenic metabolites in urine and feces of DMA(V)-exposed rats and
mice has been reported in several studies (Hughes and Kenyon, 1998; Marafante et al., 1987;
Suzuki et al., 2004a; Yoshida et al., 1997, 1998, 2001, 2003). These metabolites were in
addition to DMA(III) and TMAO and some contained one or two sulfur atoms (Yoshida et al.,
2003). Hansen et al. (2004) reported that the methylated thioarsenical, DMTA, had long been
misidentified as DMA(III). In addition, TMAO, a product of DMA(V) metabolism, is a
precursor of one of the metabolites (Kuroda et al., 2004). Intestinal bacteria are thought to have
a role in the formation of some of these metabolites (Yoshida et al., 2001; Kuroda et al.,
2004). However, two of the metabolites have been detected in livers of rats administered DMA
(V), DMA(III), MMA(V) or MMA(III) intravenously and in incubations of DMA(III) with rat
liver supernatants (Suzuki et al., 2004b). The two metabolites are dimethylthioarsinous acid
and DMTA. More recently, mono-and dimethylated thioarsenicals have been detected in urine
of rats and hamsters administered arsenite (Naranmandura et al., 2007). Raml et al. (2007) have
also recently reported that DMTA is a metabolite found in urine of Bangladeshi women who
live in an area with high levels of iAs in the drinking water. Methylated thioarsenic compounds,
some of which were detected in the urine of mice in the present study, are of interest, not only
because of their chemical structure, but also because of their potential for toxicity. DMTA and
the unknown sulfur arsenic compound formed by bacteria from DMA(V) in the presence of
cysteine are more cytotoxic than DMA(V) (Kuroda et al., 2004; Raml et al., 2007). The
identification of these methylated thioarsenicals in vivo and in excreta demonstrates the
complexity of arsenic metabolism and its potential role in arsenic toxicity.
A limitation of this study is the number of animals used, particularly in the metabolism studies.
In the dosimetry study, the coefficient of variation (CV) in the distribution and concentration
data averaged 26% (mean range 16–51%), indicating that the overall variability of these data
was reasonable. None of the standard deviations exceeded the mean value (CV > 100%). Much
greater variability was observed in the metabolism study, particularly in the analysis of iAs in
the tissues. Several of these CV values for iAs in control and treated animals exceeded 100%.
However, in the analysis of parent (DMA(V) or DMA (III)) or metabolite (DMA(III), TMAO,
DMTA or TMAS), the majority of the CV values, although high, were less than 100%.
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Certainly the addition of more animals to this portion of the study would have reduced the
variability in the data.
Because the dimethylated arsine generated from DMTA coelutes with the arsine generated
from DMA(III), it is possible that urinary DMTA contributes to the concentration of DMA(III)
as determined by HG-AAS. The contribution of DMTA to the estimated concentration of DMA
(III) is limited by its low efficiency of arsine generation in the presence of L-cysteine (~35%)
compared to DMA(III) (Hernandez-Zavala et al., in press). The concentration of DMTA in
urine was estimated as 3 μM using HPLC-ICP-MS and suggests that the error in estimation of
DMA(III) in urine by HG-AAS would be fairly small.
In summary, dose affected the absorption, metabolism, distribution and excretion of DMA(V)
administered orally to mice. These processes of DMA(V) disposition occurred rapidly. DMA
(V) was metabolized to DMA(III), TMAO, DMTA and TMAS, all of which were detected in
urine. DMA(III) was metabolized to TMAO, DMTA and TMAS, which were also detected in
urine. Parent compound (DMA(V) and DMA(III)) was also detected in urine, indicating these
arsenicals are not completely metabolized but are also mobilized for excretion. Administered
dose also affected the metabolism of DMA(V), as a lower percentage of the dose was
metabolized in the high dose group. The lower absorption and metabolism of high doses of
DMA(V) as well as its rapid excretion may partly explain the low acute toxicity of this organic
arsenical.
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Distribution of DMA(V)-derived radioactivity (% dose) in tissues of mice after po
administration of 0.6 (●) or 60 (○) mg As/kg [14C]-DMA(V). The data represent mean±SD,
N=4. Significant dose effects (p<0.05) on the concentration of DMA(V)-derived radioactivity
in tissues were observed; *, significantly greater than 60 mg As/kg.
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Concentration–time profiles of DMA(V)-derived radioactivity, based on % dose/g, in tissues
of mice after po administration of 0.6 (●) or 60 (○) mg As/kg [14C]-DMA(V). The data
represent mean±SD, N=4. Significant dose effects (p<0.05) on the concentration of DMA(V)-
derived radioactivity in tissues were observed; *, significantly greater than 60 mg As/kg.
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Concentration–time profiles of DMA(V)-derived radioactivity, based on ng As/g, in tissues of
mice after po administration of 0.6 (●) or 60 (○) mg As/kg [14C]-DMA(V). The data represents
mean±SD, N=4.
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Cumulative excretion of DMA(V)-derived radioactivity in urine and feces of mice after po
administration of 0.6 (●) or 60 (○) mg As/kg [14C]-DMA (V). The data represents mean±SD,
N=4. Significant dose effects (p<0.05) on the cumulative % dose of DMA(V)-derived
radioactivity excreted in urine and feces were observed. *, significantly greater than 60 mg As/
kg; #, significantly greater than 0.6 mg As/kg.
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Table 2
Speciated di- and trimethyl arsenicals (μg As/ml) detected by HG-AAS in 24-h cumulative urine following oral
administration of DMA(V) or DMA(III)
Chemical Dose (mg As/kg) DMA(V) DMA(III) TMAO
Control – 0.02±0.03 a 0.03±0.02 0.16±0.17
DMA(III) 0.6 1.52±2.56 1.48±0.57 2.61±1.17
DMA(V) 0.6 2.99±1.86 0.14±0.08 2.38±1.53
DMA(V) b 60 242.93±74.34 6.83±4.65 55.36±31.01




MMA(V) levels were 5.58±9.68 μg As/ml.
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Table 3
Concentration of methylated thioarsenicals (μg As/ml) detected by HPLC-ICP-MS in 24-h cumulative urine of control
and DMA(V) or DMA(III)-treated mice
Chemical Dose (mg As/kg) DMTA TMAS
Control – 0.010±0.002 a 0.003±0.001
DMA(III) 0.6 0.10±0.05 0.02±0.01
DMA(V) 0.6 0.16±0.10 0.15±0.16
DMA(V) 60 0.23±0.19 0.14±0.09
a
Mean±SD, N=3.
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